UA100131C2 - ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ - Google Patents

ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ

Info

Publication number
UA100131C2
UA100131C2 UAA201007627A UAA201007627A UA100131C2 UA 100131 C2 UA100131 C2 UA 100131C2 UA A201007627 A UAA201007627 A UA A201007627A UA A201007627 A UAA201007627 A UA A201007627A UA 100131 C2 UA100131 C2 UA 100131C2
Authority
UA
Ukraine
Prior art keywords
receptor antagonists
oxepine
dibenzo
mineralocorticoid receptor
derived
Prior art date
Application number
UAA201007627A
Other languages
English (en)
Russian (ru)
Inventor
Константінос Гавардінас
Прабхакар Кондаї Джадхав
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA100131(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA100131C2 publication Critical patent/UA100131C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Цей винахід пропонує сполуку Формули (І): EMBED ISISServer (І), та способи лікування фізіологічних розладів, зокрема застійної серцевої недостатності, гіпертензії, діабетичної нефропатії або хронічної хвороби нирок. Цей винахід має відношення до нестероїдних антагоністів рецепторів мінералокортикоїдів.
UAA201007627A 2007-12-19 2008-12-09 ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ UA100131C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
UA100131C2 true UA100131C2 (uk) 2012-11-26

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007627A UA100131C2 (uk) 2007-12-19 2008-12-09 ПОХІДНІ 6Н-ДИБЕНЗО[b,e]ОКСЕПІНУ ЯК НЕСТЕРОЇДНІ АНТАГОНІСТИ РЕЦЕПТОРІВ МІНЕРАЛОКОРТИКОЇДІВ

Country Status (34)

Country Link
US (1) US7994164B2 (uk)
EP (2) EP2537845B1 (uk)
JP (1) JP5562866B2 (uk)
KR (1) KR101254382B1 (uk)
CN (1) CN101903377B (uk)
AR (1) AR069554A1 (uk)
AU (1) AU2008343524B2 (uk)
BR (1) BRPI0820805A2 (uk)
CA (1) CA2710409C (uk)
CL (1) CL2008003600A1 (uk)
CO (1) CO6300953A2 (uk)
DK (1) DK2235007T3 (uk)
DO (1) DOP2010000185A (uk)
EA (1) EA017668B1 (uk)
EC (2) ECSP10010266A (uk)
ES (2) ES2459318T3 (uk)
GT (1) GT201000179A (uk)
HK (1) HK1144284A1 (uk)
HR (1) HRP20120916T1 (uk)
IL (1) IL206353A (uk)
MA (1) MA31910B1 (uk)
MX (1) MX2010006911A (uk)
MY (1) MY150474A (uk)
NZ (1) NZ586300A (uk)
PE (1) PE20091057A1 (uk)
PL (1) PL2235007T3 (uk)
PT (1) PT2235007E (uk)
RS (1) RS52594B (uk)
SI (1) SI2235007T1 (uk)
TN (1) TN2010000292A1 (uk)
TW (1) TWI431010B (uk)
UA (1) UA100131C2 (uk)
WO (1) WO2009085584A1 (uk)
ZA (1) ZA201004257B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
KR20100098534A (ko) 2007-12-19 2010-09-07 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
KR101312179B1 (ko) * 2009-03-12 2013-09-26 일라이 릴리 앤드 캄파니 미네랄로코르티코이드 수용체 길항제 및 사용 방법
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
WO2016001631A1 (en) 2014-06-30 2016-01-07 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
EA201790868A1 (ru) * 2014-11-21 2017-10-31 Эли Лилли Энд Компани 1,2-бензотиазольные соединения для лечения почечного расстройства
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
MX2019003339A (es) * 2016-09-24 2019-06-03 Kbp Biosciences Co Ltd Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso.
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
WO2000059884A1 (en) 1999-01-26 2000-10-12 Dana-Farber Cancer Institute, Inc. Pharmaceutically active compounds and methods of use thereof
PT1448566E (pt) * 2001-11-21 2006-08-31 Kyowa Hakko Kogyo Kk Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) * 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
RS20090208A (en) 2006-10-31 2010-06-30 Pfizer Products Inc. Pyrazoline compounds as mineralocorticoid receptor antagonists
US20100120736A1 (en) 2007-03-29 2010-05-13 N.V. Organon Mineralocorticoid Receptor Antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CA2711887A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
KR101312179B1 (ko) 2009-03-12 2013-09-26 일라이 릴리 앤드 캄파니 미네랄로코르티코이드 수용체 길항제 및 사용 방법

Also Published As

Publication number Publication date
EA201070762A1 (ru) 2010-12-30
EP2537845A1 (en) 2012-12-26
ECSP12012048A (es) 2012-08-31
EA017668B1 (ru) 2013-02-28
NZ586300A (en) 2012-06-29
CN101903377B (zh) 2014-07-09
TW200930721A (en) 2009-07-16
US7994164B2 (en) 2011-08-09
CL2008003600A1 (es) 2010-02-19
MA31910B1 (fr) 2010-12-01
RS52594B (en) 2013-04-30
BRPI0820805A2 (pt) 2015-06-16
AU2008343524A1 (en) 2009-07-09
KR20100082866A (ko) 2010-07-20
TN2010000292A1 (en) 2011-11-11
JP5562866B2 (ja) 2014-07-30
HK1144284A1 (en) 2011-02-11
IL206353A (en) 2014-06-30
CA2710409C (en) 2012-11-06
EP2235007B1 (en) 2012-10-31
ES2459318T3 (es) 2014-05-09
US20090163472A1 (en) 2009-06-25
HRP20120916T1 (hr) 2012-12-31
WO2009085584A1 (en) 2009-07-09
IL206353A0 (en) 2010-12-30
TWI431010B (zh) 2014-03-21
SI2235007T1 (sl) 2013-01-31
PT2235007E (pt) 2013-01-22
EP2235007A1 (en) 2010-10-06
ES2396605T3 (es) 2013-02-22
MX2010006911A (es) 2010-10-05
PE20091057A1 (es) 2009-07-20
JP2011507868A (ja) 2011-03-10
MY150474A (en) 2014-01-30
PL2235007T3 (pl) 2013-03-29
DOP2010000185A (es) 2010-09-15
DK2235007T3 (da) 2012-12-17
CN101903377A (zh) 2010-12-01
KR101254382B1 (ko) 2013-04-15
AR069554A1 (es) 2010-02-03
ZA201004257B (en) 2011-11-30
CA2710409A1 (en) 2009-07-09
CO6300953A2 (es) 2011-07-21
ECSP10010266A (es) 2010-07-30
AU2008343524B2 (en) 2012-03-08
EP2537845B1 (en) 2014-03-19
GT201000179A (es) 2012-04-16

Similar Documents

Publication Publication Date Title
TN2010000292A1 (en) 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
WO2007133653A3 (en) Methods for treating blood disorders
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
NO20085257L (no) Purinonderivater som HM74a-agonister
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
WO2007121154A3 (en) Substituted benzothiazole kinase inhibitors
WO2008059339A3 (en) Isoquinoline derivatives as vanilloid receptor modulators
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
WO2006120472A3 (en) Novel beta-steroid compounds
EA200801240A1 (ru) Новые способы получения производных циклопропиламида
MY163348A (en) Primary amine diazeniumdiolate heterocyclic derivatives
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists
SV2009002893A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida ref. prd2560
WO2007142904A3 (en) Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands
WO2007084591A3 (en) Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
WO2010146551A3 (en) Orally disintegrating compositions comprising antihypertensive agents
SE0701694L (sv) Nya bronkdilaterande a,b-omättade amider
DE602007012683D1 (de) Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
CY1113668T1 (el) Μη στεροειδεις ανταγωνιστες μεταλλoκoρτικoειδους υποδοχεα προερχομενοι απο 6η-διβενζο[β,ε]οξεπινη